LEWISBERRY, Pa., Feb. 16 /PRNewswire-FirstCall/ -- Unilife Corporation (Company) ( UNIS, ASX: UNS) today announced that the Company's common stock began trading on the NASDAQ Global Market on Tuesday, February 16, 2010, under the ticker symbol "UNIS."
"This is a major step for Unilife Corporation, signifying the completion of its transition from the Australian Stock Exchange into a publicly listed U.S. company. I believe moving the Company to the U.S. and listing our common stock on a major international exchange complements our rapid emergence as a global leader for innovative safety medical devices," stated Alan Shortall, CEO of Unilife.
Investors wishing to trade on either the NASDAQ or ASX are invited to visit the Company's website (www.unilife.com) to access information on Unilife Corporation, including a list of Frequently Asked Questions. The Company has also opened an Investor Hotline to assist with shareholder inquiries. The inquiry hotline numbers are 1-800-632-680 (Australia toll free), +1-866-496-5819 (US toll free) and or +61 2 8256 3394 (International).
Unilife is also pleased to advise that CEO Alan Shortall will preside over the NASDAQ closing bell ceremony on Monday, February 22, 2010. Members of Unilife's management team and guests will join Mr. Shortall at the ceremony, which will take place at the NASDAQ MarketSite in Times Square and will be broadcast live.
About Unilife Corporation
Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
Unilife's main product is the Unifill™ ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. Unilife has a strategic partnership with sanofi-aventis, a large global pharmaceutical company, pursuant to which it has paid Unilife a euro 10 million exclusivity fee and has committed to pay up to an additional euro 17 million to fund an industrialization program for the Unifill™ syringe. Upon the scheduled completion of the industrialization program in late 2010, Unilife expects to commence the supply and sale of the Unifill™ syringe to sanofi-aventis. Unilife is also in discussions with other pharmaceutical companies that are seeking to obtain access to the Unifill™ syringe.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our future reports which we will file with the Securities and Exchange Commission.
Investor Contacts (US): Todd Fromer / Garth Russell Stuart Fine KCSA Strategic Communications Carpe DM Inc Phone + 1 212-682-6300 Phone + 1 908 469 1788 Investor Contacts (Australia) Jeff Carter Unilife Corporation Phone + 61 2 8346 6500
SOURCE Unilife Corporation
|SOURCE Unilife Corporation|
Copyright©2010 PR Newswire.
All rights reserved